Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons

University of Manitoba

Overview

Objectives: To determine whether nabilone, a synthetic cannabinoid, alleviates spasticity in people with spinal cord injury (SCI). Methods: Twelve subjects were enrolled in this double-blind, placebo-controlled, crossover study. They received either nabilone or placebo during the first four-week period (0.5mg OD with option to increase to 0.5mg BID), then outcome measures were assessed. After a two-week washout, subjects were crossed-over to the opposite arm. The primary outcome was the Ashworth scale for spasticity in the most involved muscle group, chosen by the subject and clinician. The secondary outcomes included Spasm Frequency Scale, Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle groups of each side of the body, and the Clinician's and Subject's Global Impression of Change .

Study Type

INTERVENTIONAL

Conditions

Spasticity in Spinal Cord Injured Persons

Interventions

nabilone then placeboDRUG

The subjects were first on Nabilone, then crossed over to placebo

placebo then nabiloneDRUG

the subjects were first on placebo then crossed over to nabilone

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with spinal cord injury were eligible for the study if they are 18-65 years old, have C5 (ASIA A-D) and below and the injury occurred greater than 1 year previously. They had to have stable neurological level of injury with moderate spasticity (Ashworth \>/= 3) and no cognitive impairments. The spasticity medications needed to be unchanged for at least 30 days before inclusion, and no botulinum toxin injections for \> 4 months. Exclusion Criteria: They were excluded if they had: * Heart disease as cannabinoids can reduce heart rate and blood pressure * History of psychotic disorders, schizophrenia or any active psychological disorder * Previously documented sensitivity to marijuana or other cannabinoid agents * Severe liver dysfunction * Cognitive impairment * Major illness in another body area * If they were pregnant or nursing mother * Had history of drug dependency * Used smoked cannabis \< 30 days before the onset of the study or were unwilling not to smoke during the study; OR * If they fixed tendon contractures

Locations (1)

Rehabilitation hospital ,800 sherbrook St.

Winnipeg, Manitoba, Canada

Outcomes

Primary Outcomes

Ashworth scale in most involved group muscles

Time frame: 10 weeks

Secondary Outcomes

The secondary outcomes included Spasm Frequency Scale, Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle groups of each side of the body, and the Clinician's and Subject's Global Impression of Change .

Time frame: 10 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.